- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06625749
Evalúe la seguridad y eficacia del IOPCL AccuraSee ™ para implantación secundaria en la bolsa capsular para mejorar la visión cercana y/o intermedia después de una cirugía de cataratas previa
Estudio de viabilidad temprana para evaluar la seguridad y eficacia del IOPCL AccuraSee ™ para implantación secundaria en el saco capsular para mejorar la visión cercana y/o intermedia después de una cirugía de cataratas previa
This is a study to evaluate the safety and effectiveness of the AccuraSee™ intraocular pseudophakic capsular lens (IOPCL) to improve near and/or intermediate vision following previous cataract surgery.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The objective of this study is to provide preliminary evidence of the safety and efficacy of the AccuraSee intraocular pseudophakic capsular lens (IOPCL) in qualified subjects previously implanted with an Alcon monofocal intraocular lens model SN60WF, SA60WF, or SA60AT, Johnson and Johnson model ZCB00, or Zeiss model CT LUCIA 602 who desire near vision of 20/32 or better via a myopic shift in the eye to be treated.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Lynne Archer
- Número de teléfono: 714-651-6333
- Correo electrónico: larcher@onpoint-vision.com
Copia de seguridad de contactos de estudio
- Nombre: Tonya Porter
- Número de teléfono: 909-717-4493
- Correo electrónico: tporter@onpoint-vision.com
Ubicaciones de estudio
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44141
- Reclutamiento
- Midwest Vision Partners
-
Contacto:
- Julia Kantorik, COA
- Correo electrónico: jkantorik@midwestvision.com
-
Contacto:
- Erin Kus-Kreidler, COA, CCRC
- Correo electrónico: ekus-kreidler@midwestvision.com
-
Investigador principal:
- William Wiley, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
All ocular eligibility criteria refer to the study (non-dominant) eye only unless otherwise noted.
- Subjects aged 22 years and older.
- Subjects who have had cataract surgery with an Alcon monofocal intraocular lens model SN60WF, SA60WF, or SA60AT (with a lens power from 10.0D to 30.0D), or Johnson and Johnson monofocal lens model ZCB00 (with a lens power from 10.0D to 26.0D), or Zeiss monofocal lens model CT LUCIA 602 (with a lens power from 10.0D to 19.0D) clearly evidenced by photographic documentation with one of the following: patient medical record, clinic chart with labeling attached, surgical record with labeling attached, or patient identification card with make, model, power and serial number.
- Subjects who have had cataract surgery at least 6 months from the planned date of IOPCL surgery.
- Subjects who require a reading add of +1.50 to +2.50 to achieve an BCNVA of 20/32 or better.
- Subjects with uncorrected near visual acuity (UCNVA) 20/50 or worse.
- Subjects with best corrected distance visual acuity (BCDVA) 20/25 or better in both eyes.
- Subjects with uncorrected distance visual acuity (UCDVA) 20/25 or better in fellow eye.
- Subjects with best corrected near visual acuity (BCNVA) 20/32 or better.
- Subjects with a manifest refraction spherical equivalent (MRSE) in the study eye between +0.25D and +1.50D.
- Subjects with <1D of refractive cylinder determined by keratometry readings.
- Subjects with a minimum endothelial cell count of 1800 cells/mm2.
- Subjects with a tear break up time (TBUT) ≥ 7 seconds.
- Subjects with a documented monovision tolerance, or who have successfully completed a 1-week contact lens trial prior to implantation with the IOPCL.
- For subjects who are contact lens wearers, discontinuation of lens usage prior to the preoperative visit (at least 2 weeks for subjects using soft contact lenses and at least 3 weeks for hard or rigid gas permeable (RGP) lenses) except as required to test monovision acceptance.
- For subjects who are contact lens wearers, two central keratometry readings with regular mires and two manifest refractions taken at least one week apart (keratometry values must not differ by more than ±0.50D in either principal meridian in the eye to be treated).
- Subjects able to comprehend and sign a statement of informed consent.
- Subjects willing and able to complete all required postoperative visits.
- Subjects willing to abstain from pursuing any other refractive surgery for the duration of the study.
Exclusion Criteria:
- Subjects who have had cataract surgery with other than a monofocal posterior chamber intraocular lens (PCIOL).
- Subjects who have had previous laser refractive surgery.
- Subjects who have had cataract surgery with an Alcon monofocal intraocular lens model SN60WF, SA60WF, or SA60AT (with a lens power below 10.0D or greater than 30.0D), or Johnson and Johnson monofocal intraocular lens model ZCB00 (with a lens power below 10.0D or greater than 26.0D) or Zeiss monofocal lens model CT LUCIA 602 (with a lens power below 10.0D or greater than 19.0D).
- Subjects who were treated with a PCIOL in a manner that is not consistent with the labeling, contraindications, or indications for use statement.
- Subjects whose continuous curvilinear capsulorhexis is less than 4.5 mm or more than 6.0 mm in size at the time of the preoperative visit.
- Subjects who have had a Nd:YAG capsulotomy less than 1 month prior to the planned date of the IOPCL surgery.
- Subjects with a mesopic non-dilated pupil of greater than 5.5mm.
- Subjects with a mesopic dilated pupil of less than 7.0 mm.
- Subjects who have 1D or more of refractive cylinder determined by keratometry readings.
- Subjects who had cataract surgery less than 6 months from the planned date of the IOPCL surgery.
- Subjects whose PCIOL is substantially decentered (> 1.0 mm).
- Subjects with anterior capsule fibrosis and phimosis that, in the opinion of the investigator, may confound the outcome or increase the risk to the subject (e.g., excessive capsule contraction potentially obstructing the visual axis or causing late secondary complications to the PCIOL such as pseudophacodenesis and IOL tilt, decentration, or dislocation due to zonular laxity, weakness or dehiscence).
- Subjects with capsular instability.
- Subjects with an anterior capsular defect.
- Subjects with posterior capsular defect < 0.5 mm from the edge of the existing IOL (caused by Nd:YAG capsulotomy).
- Subjects with a tear or rent in the anterior or posterior capsule.
- Subjects with any corneal pathology that is either progressive or sufficient to reduce BCDVA to 20/25 or worse.
- Subjects with any corneal abnormality, other than regular corneal astigmatism, that prevents accurate assessment of fluorescein tear break up time or, in the opinion of the investigator, would confound the outcome(s) of the study.
- Subjects with active moderate to severe meibomian gland dysfunction.
- Subjects with clinically severe corneal dystrophy (e.g., epithelial, stromal, or endothelial dystrophy).
- Subjects with diagnosed degenerative visual disorders (e.g., macular degeneration or other retinal disorders) that would reduce BCDVA to 20/25 or worse.
- Subjects with recurrent severe anterior or posterior segment inflammation of unknown etiology.
- Subjects with microphthalmos.
- Subjects with previous retinal detachment.
- Subjects with diabetic retinopathy.
- Subjects with iris neovascularization.
- Subjects with a history of steroid-responsive rise in intraocular pressure (IOP), uncontrolled glaucoma or preoperative IOP >21 mmHg.
- Subjects with amblyopia in either eye.
- Subjects who have current or historical significant binocular muscle imbalances or intermittent tropias and/or fail the cover test.
- Subjects who fail to demonstrate normal perception at near (33 cm) on the Worth 4 Dot Binocular Test for binocular function (using best corrected visual acuity).
- Subjects who fail to demonstrate at least gross stereopsis (i.e., pinching fly's wings in front of test booklet) with best corrected visual acuity on the Titmus Stereo Test (at near).
- Subjects with a fundus not visible.
- Subjects with aniridia.
- Subjects with optic nerve atrophy.
- Subjects with damaged or incomplete zonules.
- Subjects with inadequate anterior leaflet coverage of the PCIOL (defined as less than 0.5 mm of anterior leaflet of capsule above where the haptics will reside).
- Subjects with damage to the PCIOL.
- Subjects with a known history of pseudoexfoliation, or pseudoexfoliation diagnosed at the preoperative visit or prior to IOPCL implantation.
- Subjects with acute, chronic or uncontrolled systemic or ocular disease that in the opinion of the investigator would increase the operative risk or confound the outcome(s) of the study.
- Subjects taking medications that, in the opinion of the investigator, may confound the outcome or increase the risk to the subject (tamsulosin hydrochloride (Flomax)) or taking other medications with similar side effects (floppy iris syndrome).
- Subjects participating in any other ophthalmic drug or device trial during the time of this investigation.
- Subjects who are pregnant or nursing women; or women of child bearing age not using medically acceptable contraceptives.
- Subjects with certain occupational and environmental visual demands (i.e. piloting an airplane, working on and operating dangerous machinery) in the opinion of the investigator would increase the post-operative risk.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Lente capsular pseudofáquica intraocular AccuraSee™ (IOPCL)
|
Intraocular pseudophakic capsular lens (IOPCL) |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Improvement in uncorrected near visual acuity (UCNVA) at 40 cm/16 inches
Periodo de tiempo: 12 months
|
Improvement in uncorrected near visual acuity (UCNVA) (at 40 cm/16 inches) at 12 months postoperatively. At least 75% of treated eyes should achieve an uncorrected near visual acuity (UCNVA) of 20/32 or better. |
12 months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Improvement in uncorrected intermediate visual acuity (UCIVA) (at 66 cm/26 inches)
Periodo de tiempo: 12 months
|
Improvement in uncorrected intermediate visual acuity (UCIVA) at 66 cm/26 inches at 12 months postoperatively. At least 75% of treated eyes should achieve a UCIVA of 20/40 or better. |
12 months
|
|
Preservation of best corrected distance visual acuity (BCDVA)
Periodo de tiempo: 12 Months
|
Proportion of eyes (< 5%) that lose two or more lines of best corrected distance visual acuity (BCDVA) (≥ 10 letters on the Early Treatment for Diabetic Retinopathy Study [ETDRS] chart). |
12 Months
|
|
Successful delivery of the intraocular pseudophakic capsular lens (IOPCL)
Periodo de tiempo: Postoperatively from 7-14 days visit through 12 months visit
|
Successful delivery of the intraocular pseudophakic capsular lens (IOPCL) (defined as no capsular tear, no visible damage to either the posterior chamber intraocular lens [PCIOL] or the IOPCL, and adequate leaflet coverage of all IOPCL haptic tabs [≥ 0.5 mm of anterior leaflet of capsule above where the haptics reside]). |
Postoperatively from 7-14 days visit through 12 months visit
|
|
PCIOL Long-term adherence and positional stability (tilt)
Periodo de tiempo: Postoperatively from 30-60 days visit through 12 months visit
|
Minimal tilt of the posterior chamber intraocular lens (PCIOL) confirmed via Anterion® AS-OCT (defined as ≤ 10 degrees between the postoperative tilt of the PCIOL and the pre-operative tilt of the PCIOL). |
Postoperatively from 30-60 days visit through 12 months visit
|
|
Intraocular Pseudophakic Capsular Lens (IOPCL) Long-term adherence and positional stability (tilt)
Periodo de tiempo: Postoperatively from 30-60 days visit through 12 months visit
|
Minimal tilt of the intraocular pseudophakic capsular lens (IOPCL) (using the posterior chamber intraocular lens [PCIOL] as a reference point) confirmed via Anterion® AS-OCT (defined as ≤ 10 degrees between the post-operative tilt of the PCIOL and the postoperative tilt of the IOPCL). |
Postoperatively from 30-60 days visit through 12 months visit
|
|
PCIOL/IOPCL Complex Long-term adherence and positional stability (decentration)
Periodo de tiempo: Postoperatively starting at 7-14 days through 12 months
|
Decentration of the posterior chamber intraocular lens/intraocular pseudophakic capsular lens (PCIOL/IOPCL complex) (defined as uniform exposed area of the PCIOL outside of the IOPCL at the vertical and horizontal meridians between ≥ 0.5 mm and ≤ 1.0 mm. |
Postoperatively starting at 7-14 days through 12 months
|
|
Intraoperative and postoperative adverse events
Periodo de tiempo: Intraoperative and Postoperative through 12 months
|
Characterization and incidence of cumulative and persistent intraoperative and post-operative adverse events. |
Intraoperative and Postoperative through 12 months
|
|
Secondary Surgical Interventions (SSIs)
Periodo de tiempo: Postoperative through 12 months
|
Incidence of secondary surgical interventions (SSIs) (e.g., removal of interlenticular opacity, repositioning of intraocular pseudophakic capsular lens [IOPCL], explant of IOPCL, repositioning of posterior chamber intraocular lens [PCIOL]) (excluding neodymium-doped yttrium aluminum garnet [Nd:YAG] treatments for posterior capsule opacification (PCO). |
Postoperative through 12 months
|
|
Endothelial Cell Counts
Periodo de tiempo: Postoperatively beginning with 120-180 days through 12 months
|
Endothelial Cell Counts (mean loss, minimum, maximum, and quartiles of endothelial cell density [ECD] loss)
|
Postoperatively beginning with 120-180 days through 12 months
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CIIPCL-022R
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .